Product Information
Registration Status: ActiveSIN15244P
GLIOLAN, POWDER FOR ORAL SOLUTION, 30 MG/ML is approved to be sold in Singapore with effective from 2017-05-26. It is marketed by LINK HEALTHCARE SINGAPORE PTE LTD, with the registration number of SIN15244P.
This product contains Aminolevulinic Acid 30mg/ml in the form of POWDER, FOR SOLUTION. It is approved for ORAL use.
This product is manufactured by IDT Biologika GmbH (DP in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indication
Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Mechanism of Action
According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).
Pharmacokinetics
- Absorption
- Oral bioavailability is 50-60%.
- Distribution
- Metabolism
- Following topical administration, synthesis into protoporphyrin IX takes place in situ in the skin.
- Elimination
Toxicity
Solution overdose have not been reported.
Active Ingredient/Synonyms
5-ALA | 5-Aminolevulinic acid | Aminolevulinic acid | dALA | δ-ALA | δ-aminolevulinic acid | Aminolevulinic acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.